Abstract
Sixty patients with Chronic Myeloid Leukemia (CML) who were on oral imatinib were included in this study. The study aimed to evaluate patients characteristic, tolerability and efficacy and clinical outcome in Iranian patients who have been treated with generic imatinib. The median age of patients was 48 years, and the median follow up was 44 months. 94% of patients achieved complete hematologic response (CHR) during the 3 months of beginning imatinib, and after 12 - 24 months of imatinib therapy 46.8% achieved molecular response. The most common non-hematologic toxicity was fluid retention (64%), fatigue (43%) and moderate to severe hematologic side effect included anemia 10%, neutropenia 10%, and thrombocytopenia 6.6%. About 13% of patients transformed into accelerated phase (AP) or blastic crisis (BC) and the death rate during this period was 7%. In conclusion, there is heterogeneity in different areas in characteristic of CML (especially in age), and also response rate and side effect of patients with CML that treated with imatinib are different.
Highlights
Chronic myeloid leukemia (CML) is a myeloproliferative disorder, and characterized by a chromosomal rear-How to cite this paper: Mozaheb, Z. and Javani, M. (2014) Regional Evaluation of Tolerability and Efficacy of Imatinib Mesylate in Patients with Chronic Phase CML in Mashhad (Iran, Southwest Asia)
The treatment of CML has been revolutionized with the use of competitive inhibitor of the Bcr-Abl tyrosine kinase, imatinib mesylate [1]
There are few studies about CML patients and their treatment in our area (Mashhad, Iran), in this study we aim to study the response rate and side effect of imatinib in our CML patients to compare with the other studies
Summary
Chronic myeloid leukemia (CML) is a myeloproliferative disorder, and characterized by a chromosomal rear-How to cite this paper: Mozaheb, Z. and Javani, M. (2014) Regional Evaluation of Tolerability and Efficacy of Imatinib Mesylate in Patients with Chronic Phase CML in Mashhad (Iran, Southwest Asia). (2014) Regional Evaluation of Tolerability and Efficacy of Imatinib Mesylate in Patients with Chronic Phase CML in Mashhad (Iran, Southwest Asia). Javani rangement of the long arms of chromosomes 9 and 22, resulting in the formation of the Philadelphia chromosome These lead to formation of a novel fusion gene Bcr-Abl, which encodes a constitutively active tyrosine kinas in transformed cells. The treatment of CML has been revolutionized with the use of competitive inhibitor of the Bcr-Abl tyrosine kinase, imatinib mesylate [1]. Imatinib mesylate a Bcr-Abl tyrosine kinas inhibitor, has been shown to induce dramatic hematologic and cytogenetic responses in CML [2] and remains the standard for first-line treatment of CML in chronic phase [3]. There are few studies about CML patients and their treatment in our area (Mashhad, Iran), in this study we aim to study the response rate and side effect of imatinib in our CML patients to compare with the other studies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
